- Conditions
- Node-positive Breast Cancer
- Interventions
- Tailored axillary surgery - both Arms, Radiotherapy - Arm A, Radiotherapy - Arm B
- Procedure · Radiation
- Lead sponsor
- University Hospital, Basel, Switzerland
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2036
- U.S. locations
- 3
- States / cities
- Bethesda, Maryland • Durham, North Carolina • Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 256
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Prostate Cancer
- Interventions
- Lymph node template, Transverse versus vertical closure, antibiotic prophylaxis, Hemostatic Agent
- Procedure · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 21 Years and older · Male only
- Enrollment
- 3,204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2027
- U.S. locations
- 5
- States / cities
- Basking Ridge, New Jersey • Montvale, New Jersey • Harrison, New York + 2 more
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
- Interventions
- therapeutic autologous lymphocytes, cyclophosphamide, aldesleukin, polymerase chain reaction, gene rearrangement analysis, lymph node biopsy, genetically engineered lymphocyte therapy, bone marrow aspiration, flow cytometry, laboratory biomarker analysis, enzyme-linked immunosorbent assay
- Biological · Drug · Genetic + 2 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Lung Cancer, Lymph Node Metastasis, Pathologic Processes
- Interventions
- Subjects undergoing a lung specimen lymph node dissection, Control group
- Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Melanoma (Skin)
- Interventions
- recombinant interferon alfa, lymphangiography, Observation
- Biological · Procedure · Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2007
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Louisville, Kentucky • New Brunswick, New Jersey + 1 more
- Conditions
- Gastric Cancer
- Interventions
- Indocyanine green
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Breast Cancer
- Interventions
- Filgrastim, Docetaxel, Doxorubicin, Surgery
- Biological · Drug · Procedure
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2012
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Muscle Invasive Bladder Cancer
- Interventions
- Radiation and chemoradiation, Radical cystectomy
- Radiation · Procedure
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Flotufolastat F-18 Gallium, Laparoscopic Radical Prostatectomy with Robotics, Pelvic Lymphadenectomy, Positron Emission Tomography, Relugolix
- Procedure · Other · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Breast Cancer, Cancer of Breast, Cancer of the Breast, Melanoma, Malignant Melanoma
- Interventions
- Sentinel lymph node biopsy, Goggle-based device with light-emitting diodes (LED), Indocynanine Green
- Procedure · Device · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Melanoma
- Interventions
- Excision of clinically detected lymph node metastasis before any systemic therapy, Excision of clinically detected lymph node metastasis after neoadjuvant systemic therapy
- Procedure
- Lead sponsor
- Craig L Slingluff, Jr
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 7
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • Ann Arbor, Michigan + 4 more
- Conditions
- Sentinel Lymph Node
- Interventions
- ICG Intervention, Near Infrared Imaging
- Drug · Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Renal Cell Carcinoma
- Interventions
- CTT1057
- Drug
- Lead sponsor
- Cancer Targeted Technology
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Breast Cancer, Ductal Carcinoma
- Interventions
- Nipple-Sparing Mastectomy, Breast Reconstruction, Axillary Surgery, Prophylactic Nipple-Areolar Complex RT
- Procedure · Radiation
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Neoplasms, Germ Cell and Embryonal
- Interventions
- Next generation genome sequencing
- Genetic
- Lead sponsor
- Nasser Hanna
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana
- Conditions
- Lymphocele After Surgical Procedure
- Interventions
- lymph node dissection using the peritoneal iliac flap approach to seal lymphatic vessels, Standard surgical approach
- Procedure
- Lead sponsor
- Hartford Hospital
- Other
- Eligibility
- 18 Years to 80 Years · Male only
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Hartford, Connecticut
- Conditions
- Bladder Cancer
- Interventions
- Gemcitabine and Cisplatin (DD GC)
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 8
- States / cities
- Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 4 more
- Conditions
- Endometrial Cancer
- Interventions
- sentinel lymph node detection, indocyanine green solution, isosulfan blue, sentinel lymph node biopsy
- Procedure · Drug
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 85 Years · Female only
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Columbus, Ohio
- Conditions
- Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
- Interventions
- Axillary Lymph Node Dissection, Enzalutamide, Laboratory Biomarker Analysis, Lymph Node Biopsy, Paclitaxel, Therapeutic Conventional Surgery
- Procedure · Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Clinical Stage 0 Gastric Cancer AJCC v8, Clinical Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIB Gastric Cancer AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Gastric Adenocarcinoma, Localized Gastric Carcinoma, Localized Gastroesophageal Junction Adenocarcinoma, Pathologic Stage 0 Gastric Cancer AJCC v8, Pathologic Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage I Gastric Cancer AJCC v8, Pathologic Stage IA Gastric Cancer AJCC v8, Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IB Gastric Cancer AJCC v8, Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIA Gastric Cancer AJCC v8, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastric Cancer AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
- Interventions
- Fluorouracil, Intensity-Modulated Radiation Therapy, Ipilimumab, Nivolumab, Oxaliplatin, Therapeutic Conventional Surgery
- Drug · Radiation · Biological + 1 more
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Bladder Cancer
- Interventions
- Specimen Ultra-High field MRI, chemotherapy, Cystectomy and Lymphadenectomy
- Procedure · Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Melanoma, Merkel Cell Carcinoma, Squamous Cell Carcinoma, Penile Carcinoma, Urethral Carcinoma, Extramammary Paget's Disease, Scrotal Carcinoma, Anal Cancer, Vulvar Cancer, Skin Cancer, Lymphadenopathy
- Interventions
- Videoscopic procedure, Open, traditional approach
- Procedure
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Cutaneous Melanoma
- Interventions
- Pembrolizumab, Talimogene Laherparepvec
- Drug
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Consensus Development
- Interventions
- Delphi Questionnaire
- Behavioral
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California